(NU/1433-47) Kargenera: The Provision of Business Consultancy to Assist Commercialisation of University Research
What the buyer wrote
The University of Southampton have developed a unique DNA based therapeutic to activate NK cells against cancer. The therapeutic is delivered intramuscularly in combination with DNA encoding the potent immune stimulating cytokine IL-15. The objective is for an Executive to jointly work with the team to bring the opportunity towards and ultimately achieve launch of a new spinout company.
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- (NU/1433-47) Kargenera: The Provision of Business Consultancy to Assist Commercialisation of University Research
- How they are buying
- Advertised, shortlist firstSuppliers applied to be considered, and the buyer picked who went on to bid.
- Type
- services
- Dynamic market
- Yes: you can apply to join at any time. How these work
- Where
- in the North East
- Kind of work
- Professional services
Who the buyer named
University of Newcastle upon Tyne t/a Newcastle University was the named contact on this notice.